Medindia10d
Gemcitabine and Docetaxel Show Superior Results Over BCG in Bladder Cancer
A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...
Cure Today6d
Breaking Down the Safety of BCG in Patients With NMIBC
BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
BOSTON & MONTREAL, February 04, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage ...
Renal & Urology News8d
Gemcitabine-Docetaxel Appears More Effective for High-Risk NMIBC
Sequential gemcitabine docetaxel is increasingly viewed as a valid option for BCG unresponsive non-muscle-invasive bladder cancer (NMIBC).
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
The Program Committee of the AUA has accepted the Theralase®'s abstract titled: ' Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive ...
Theralase Technologies, Inc.: Theralase Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
TORONTO, ON / ACCESS Newswire / January 27, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the resear ...
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BOSTON & MONTREAL, January 31, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic ...
Yahoo Finance28d
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
"Patients with BCG-naïve high-risk non-muscle invasive bladder cancer have high rates of recurrence and progression," said Neal Shore, M.D., FACS, Medical Director for the Carolina Urologic ...